Screening of Medicinal Plants for PPARα and PPARγ Activation and Evaluation of Their Effects on Glucose Uptake and 3T3-L1 Adipogenesis

Abstract

Medicinal plants are a rich source of ligands for nuclear receptors. The present study was aimed to screen a collection of plant extracts for PPARα/γ-activating properties and identify the active extract that can stimulate cellular glucose uptake without enhancing the adipogenesis. A reporter gene assay was performed to screen ethanolic extracts of 263 plant species, belonging to 94 families, for activation of PPARα and PPARγ. Eight extracts showed activation of PPARγ, while 22 extracts showed activation of PPARα. The extracts of five plants (Daphne gnidium, Illicium anisatum, Juniperus virginiana, Terminalia chebula, and Thymelaea hirsuta) showed activation of both PPARα and PPARγ and out of them, D. gnidium and T. hirsuta markedly increased PPARα/γ protein expression. All five extracts showed an increase in cellular glucose uptake. Of the five dual agonists, T. chebula and T. hirsuta did not show any increase in differentiation of 3T3-L1 preadipocytes, but I. anisatum caused an increase in adipogenesis, while D. gnidium and J. virginiana were toxic to adipocytes. The adipogenic effect of rosiglitazone was antagonized by T. chebula and T. hirsuta. It was concluded that T. hirsuta and T. chebula retain the property of elevating glucose uptake as PPARα/γ dual agonists without the undesired side effect of adipogenesis. This is the first report to reveal the PPARα/γ dual agonistic action and glucose uptake enhancing property of T. hirsuta and T. chebula.

Key words

type 2 diabetes - PPARα and PPARγ activation - glucose uptake stimulation - adipocyte differentiation - Thymelaea hirsuta - Thymelaeaceae - Terminalia chebula - Combretaceae

• References

• 1 Sacks DB, McDonald JM. The pathogenesis of type II diabetes mellitus. A polygenic disease. Am J Clin Pathol 1996; 105: 149-156
• 2 Dagogo-Jack S, Santiago JV. The natural history of type 2 diabetes. A Special Report: Managing Type 2 Diabetes. New Science and New Strategies. Post Graduate Medicine. New York: McGraw-Hill Companies, Inc.; 1998
• 3 DeFronzo RA. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-687
• 4 Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607
• 5 Attele AS, Zhou YP, Xie JT, Wu JA, Zhang L, Dey L, Pugh W, Rue PA, Polonsky KS, Yuan CS. Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes 2002; 51: 1851-1858
• 6 Yki-Yarvinen H. Toxicity of hyperglycaemia in type 2 diabetes. Diabet Metab Rev 1998; 14: S45-S50
• 7 Zimmet PZ. Diabetes epidemiology as a tool to trigger diabetes research and care. Diabetologia 1999; 42: 499-518
• 8 Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005; 26: 244-251
• 9 Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrinol Rev 1999; 20: 649-688
• 10 Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor (PPAR) γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994; 135: 798-800
• 11 Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM. The structure activity relationship between peroxisome proliferator activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996; 39: 665-668
• 12 Turmelle YP, Shikapwashya O, Tu S, Hruz PW, Yan Q, Rudnik DA. Rosiglitazone inhibits mouse liver regeneration. FASEB J 2006; 20: 2609-2611
• 13 de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, Burkey BF. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001; 50: 1863-1871
• 14 Alarcon-Aguilara FJ, Roman-Ramos R, Perez-Gutierrez S, Aguilar-Contreras A, Contreras-Weber CC, Flores-Saenz JL. Study of the anti-hyperglycemic effect of plants used as antidiabetics. J Ethnopharmacol 1998; 61: 101-110
• 15 Yun JW. Possible anti-obesity therapeutics from nature – A review. Phytochemistry 2010; 71: 1625-1641
• 16 Prabhakar PK, Doble M. A target based therapeutic approach towards diabetes mellitus using medicinal plants. Curr Diabet Rev 2008; 4: 291-308
• 17 Liu Q, Chen L, Hu L, Guo Y, Shen X. Small molecules from natural sources, targeting signaling pathways in diabetes. Biochem Biophys Acta 2010; 1799: 854-865
• 18 Huang THW, Teoh AW, Lin BL, Lin DSH, Roufogalis B. The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome. Pharmacol Res 2009; 60: 195-206
• 19 Huang TH, Kota BP, Razmovski V, Roufogalis BD. Herbal or natural medicines as modulators of peroxisome proliferator-activated receptors and related nuclear receptors for therapy of metabolic syndrome. Basic Clin Pharmacol Toxicol 2005; 96: 13-14
• 20 Rau O, Wurglics M, Dingermann T, Abdel-Tawab M, Schubert-Zsilavecz M. Screening of herbal extracts for activation of the human peroxisome proliferators-activated receptor. Pharmazie 2006; 61: 952-956
• 21 Laville M, Andreelli F. Mechanisms for weight gain during blood glucose normalization. Diabet Metab 2000; 26: 42-45
• 22 Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FJ, Auwerx J. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice. J Biol Chem 1997; 272: 27307-27312
• 23 Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162: 2597-2604
• 24 Jarald E, Joshi SB, Jain DC. Diabetes and Herbal Medicines. Iran J Pharmacol Ther 2008; 7: 97-106
• 25 Flevét C, Fruchart JC, Staels B. PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 2006; 6: 606-614
• 26 Xu J, Ma M, Purcell WM. Characterization of some cytotoxic endpoints using rat liver and HepG2 spheroids as in vitro models and their application in hepatotoxicity studies. I. Glucose metabolism and enzyme release as cytotoxic markers. Toxicol Appl Pharmacol 2003; 189: 100-111
• 27 El Amrani F, Rhallab A, Alaoui T, El Badaoui K. Hypoglycaemic effect of Thymelaea hirsuta in normal and streptozotocin-induced diabetic rats. J Med Plants Res 2009; 3: 625-629
• 28 Verma N, Singh AP, Amresh G, Sahub PK, Singha A, Mishrab N. Review on wonderful and miraculous Triphala. J Pharm Res 2011; 4: 690-694
• 29 Bnouham M, Mekhfi H, Legssyer AK, Ziyyat A. Medicinal plants used in the treatment of diabetes in Morocco. Int J Diabet Metab 2002; 10: 33-50
• 30 Singh I, Singh PK, Bhansali S, Shafiq N, Malhotra S, Pandhi P, Singh AP. Effects of three different doses of a fruit extract of Terminalia chebula on metabolic components of metabolic syndrome, in a rat model. Phytother Res 2010; 24: 107-112
• 31 Ntambi JM, Kim YC. Adipocyte differentiation and gene expression. J Nutr 2000; 130: S3122-S3126
• 32 Rosen ED. The transcriptional basis of adipocyte development. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 31-34
• 33 Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM. PPARγ is required for the differentiation of adipose tissue in vivo and in vitro . Mol Cell 1999; 4: 611-617
• 34 Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998; 339: 953-959
• 35 Kumanyika S, Jeffery RW, Morabia A, Ritenbaugh C, Antipatis VJ. Obesity prevention: the case for action. Public Health Approaches to the Prevention of Obesity (PHAPO) Working Group of the International Obesity Task Force (IOTF). Int J Obes Relat Metab Disord 2002; 26: 425-436
• 36 Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998; 101: 1354-1361
• 37 Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia 2000; 43: 1498-1506
• 38 Christensen KB, Minet A, Svenstrup H, Grevsen K, Zhang H, Schrader E, Rimbach G, Wein S, Wolffram S, Kristiansen K, Christensen LP. Identification of plant extracts with potential antidiabetic properties: effect on human peroxisome proliferator-activated receptor (PPAR), adipocyte differentiation and insulin-stimulated glucose uptake. Phytother Res 2009; 23: 1316-1325
• 39 Heim M, Johnson J, Boess F, Bendik I, Weber P, Hunziker W, Flühmann B. Phytanic acid, a natural peroxisome proliferator-activated receptor (PPAR) agonist, regulates glucose metabolism in rat primary hepatocytes. FASEB J 2002; 16: 718-720
• 40 Avula B, Wang YH, Wang M, Shen YH, Khan IA. Simultaneous determination and characterization of tannins and triterpene saponins from the fruits of various species of Terminalia and Phyllantus emblica using a UHPLC-UV-MS method: application to triphala. Planta Med 2013; 79: 181-188
• 41 Pfundstein B, El DSK, Hull WE, Haubner R, Erben G, Owen RW. Polyphenolic compounds in the fruits of Egyptian medicinal plants (Terminalia bellerica, Terminalia chebula and Terminalia horrida): Characterization, quantitation and determination of antioxidant capacities. Phytochemistry 2010; 71: 1132-1148
• 42 Brooks G, Evans AT, Aitken A, Evans FJ, Rizk AFM, Hammouda FM, El-Missiry MM, Ismail SE. Daphnane diterpenes of Thymelaea hirsuta . Phytochemistry 1990; 29: 2235-2237
• 43 Miyamae Y, Villareal MO, Abdrabbah MB, Isoda H, Shigemori H. Hirseins A and B, daphnane diterpenoids from Thymelaea hirsuta that inhibit melanogenesis in B16 melanoma cells. J Nat Prod 2009; 72: 938-941
• 44 Trigui M, Hsouna AB, Tounsi S, Jaoua S. Chemical composition and evaluation of antioxidant and antimicrobial activities of Tunisian Thymelaea hirsuta with special reference to its mode of action. Indian Crop Prod 2013; 41: 150-157
• 45 Rizk AM, Hammouda FM, Ismail SI. Phytochemical investigation of Thymelea hirsuta. II. Lipid fraction. Planta Med 1974; 26: 346-358
• 46 Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63
• 47 Mizuno CS, Ma G, Khan S, Patny A, Avery MA, Rimando AM. Design, synthesis, biological evaluation and docking studies of pterostilbene analogs inside PPARα . Bioorg Med Chem 2008; 16: 3800-3808
• 48 Jaradat MS, Wongsud B, Phornchirasilp S, Rangwala SM, Shams G, Sutton M, Romstedt KJ, Noonan DJ, Feller DR. Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H2 synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol 2001; 62: 1587-1595
• 49 Chen QC, Zhang WY, Jin W, Lee IS, Min BS, Jung HJ, Na M, Lee S, Bae K. Flavonoids and isoflavonoids from Sophorae flos improve glucose uptake in vitro . Planta Med 2010; 76: 79-81
• 50 Wang L, Xu ML, Rasmussen SK, Wang MH. Vomifoliol 9-O-α-arabinofuranosyl (1 → 6)-β-D-glucopyranoside from the leaves of Diospyros kaki stimulates the glucose uptake in HepG2 and 3 T3-L1 cells. Carbohydr Res 2011; 346: 1212-1216
• 51 Kasturi R, Joshi VC. Hormonal regulation of stearoyl coenzyme A desaturase activity and lipogenesis during adipose conversion 3 T3-L1 cells. J Biol Chem 1982; 257: 12224-12230